Blonanserin

DB09223InvestigationalSmall molecule

Blonanserin is an atypical antipsychotic approved in Japan in January, 2008. It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As a... As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics.

Mechanism: Blonanserin binds to and inhibits dopamine receptors D2 and D3 as well as the serotonin receptor 5-HT2A with high affinity. Blonanserin has low affinity for other dopamine and serotonin receptors as well as muscarinic, adrenergic, and histamine receptors. This reduces dopaminergic and serotonergic neurotransmission which is thought to produce a reduction in positive and negative symptoms of schizophrenia respectively.
Curator reviewed · 1 reference
Primary indication: Used for the treatment of schizophrenia.Curator reviewed
Formula / weight: C₂₃H₃₀FN₃ · 367.512 g/mol (avg)
Code names: AD-5423

Resolves to

Compound

UNIIAQ316B4F8CCAS132810-10-7ChEMBLCHEMBL178803ChEBI31296PubChem125564KEGGD01176

Structure

InChIKeyXVGOZDAJGBALKS-UHFFFAOYSA-NSMILESCCN1CCN(CC1)C1=NC2=C(CCCCCC2)C(=C1)C1=CC=C(F)C=C1

Targets

P14416DRD2P35462DRD3P28223HTR2A

What you can answer from here — as of February 21, 2021

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,475Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

25+ReferencesStructured and connected to the statements they support

Which drugs share a target with Blonanserin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account